American businesses have a long history of risk taking, even from their whaling days, writes Tom Nicholas
Edelweiss Securities' head of research sees huge potential in Dr Reddy's, and also an attractive valuation
In Ankleshwar, feisty MSMEs that survived the Chinese onslaught say that the fight against red tapism is harder
Dr Reddy’s promoter GV Prasad buys in the open market amid growing headwind
MP Ramachandran, CMD, Jyothy Laboratories on five ways to ensure a successful post-merger integration
How Jyothy Laboratories sparked growth in brands bought from German consumer giant Henkel
Ambi MG Parameswaran decodes Nassim Taleb's acerbic take on being accountable for one's decisions in 'Skin In The Game'
By focusing on its strength in manufacturing lyophilized injectables, Gufic Biosciences has made a strong comeback and wants to aggressively push into the EU market next
When change sets in, companies initially live in denial, and when it catches up, it’s too late
Secret Diary of Ajay Piramal — Part 2
Betting on quality and structural themes is the key to Gautam Sinha Roy’s investing success
The independent market expert believes Jyothy Labs’ prima facie bad news should be seen as an investment opportunity
A strong product pipeline and receding US FDA threat could well turn the tide in favour of the beleaguered pharma players
Is the Internet changing the way we think? Author Nicholas Carr finds out in 'The Shallows'
The domestic pharma industry, which is already battling the US FDA, has now to contend with regulatory challenges at home
An extract from Nassim Nicholas Taleb's book 'Antifragile: Things that gain from disorder'
About 200 rare books on Indian art recently changed hands at an online auction
Hyderabad’s pharma players are adapting to a regulatory backlash and fighting back against dumping from China
After a dream run, Sun Pharma is grappling with growth and regulatory issues. Can the country’s biggest drug maker rediscover its mojo?
Trivitron Group's MD wants to leverage his expertise in healthcare to fund disruptive ideas in that space
Can Jyothy Laboratories’ transformation help it outrun its competitors in the FMCG market?
Jyothy Laboratories' joint managing director and CFO on his favourite artist and much more
As their tax holiday draws to a close, many pharmaceutical units are unsure about their future in the hilly Baddi
Drug majors are shifting clinical trials out of India as lawmakers turn on the heat
Nephroplus’ Vikram Vuppala’s eight-wheelers can outrun any fancy car
The Rising popularity of the deodorant segment has drawn names big and small, but only a handful will thrive